Rezolute (NASDAQ:RZLT) Issues Earnings Results

Rezolute (NASDAQ:RZLT) posted its quarterly earnings data on Thursday. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14), Zacks reports.

Rezolute Stock Performance

Shares of NASDAQ:RZLT traded up $0.26 during trading hours on Friday, hitting $5.08. The stock had a trading volume of 1,514,825 shares, compared to its average volume of 440,479. The stock’s fifty day simple moving average is $4.62 and its 200 day simple moving average is $3.72. Rezolute has a 1-year low of $0.72 and a 1-year high of $6.10. The firm has a market capitalization of $203.89 million, a price-to-earnings ratio of -4.46 and a beta of 1.18.

Analyst Ratings Changes

RZLT has been the subject of a number of analyst reports. Craig Hallum assumed coverage on shares of Rezolute in a research report on Tuesday, June 4th. They issued a “buy” rating and a $14.00 price objective for the company. Maxim Group upped their target price on shares of Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, August 6th. JMP Securities reiterated a “market outperform” rating and set a $7.00 price objective on shares of Rezolute in a research note on Friday. BTIG Research increased their price objective on shares of Rezolute from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, September 10th. Finally, Guggenheim started coverage on shares of Rezolute in a research note on Tuesday, August 27th. They set a “buy” rating and a $11.00 price objective on the stock. Seven analysts have rated the stock with a buy rating, According to MarketBeat, Rezolute presently has a consensus rating of “Buy” and an average price target of $11.57.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.